Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
January 15, 2025

Cycle expands MS treatment portfolio with Banner Life Sciences acquisition

Cycle Pharmaceuticals has completed the acquisition of Banner Life Sciences, including BAFIERTAM (monomethyl fumarate) product, a US Food and Drug Administration (FDA)-approved treatment for relapsing forms of multiple sclerosis (MS) in the adult population.

Continue
The acquisition involves the inclusion of multiple sclerosis therapy, BAFIERTAM. Credit: Robina Weermeijer on Unsplash.
January 13, 2025

JW Therapeutics’ Carteyva receives breakthrough therapy status for r/r LBCL

The autologous chimeric antigen receptor T cell immunotherapy product is developed independently by JW Therapeutics. Credit: Nappy/unsplash.com.
January 10, 2025

RheumaGen secures $15m in Series A funding to advance RA therapies

RG0401 is tailored to edit the human leukocyte antigen gene’s DNA markers. Credit: digitale.de on Unsplash.

Contracts

August 9, 2024

Bavarian Nordic secures $156.8m US vaccine deal

The vaccine is marketed under various brand names. Credit: Mathurin NAPOLY / matnapo on Unsplash.

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Harbour BioMed, Moderna partner on immunotherapies development

Deals

Deals December 31, 2024

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Pharmaceutical Business Review

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Q32 Bio concludes merger deal with Homology Medicines

Popular

  1. Parvus and Resilience expand partnership to develop IBD drug candidate
  2. FDA grants priority review to Dizal’s sunvozertinib NDA for NSCLC treatment
  3. Star Therapeutics’ von Willebrand disease therapy gains FDA fast track status
  4. China’s NMPA approves Astellas’ advanced gastric cancer combo therapy
  5. China’s NMPA approves Innovent’s taletrectinib for NSCLC treatment

PRESS RELEASES

Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group
Gerresheimer Successfully Completes Acquisition of Blitz LuxCo, the Holding Company of the Bormioli Pharma Group
Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site
Gerresheimer Builds New Production Capacities for Glass Syringes at Skopje Site
Tosoh Bioscience – Separation & Purification Expands European Headquarters in Griesheim, Germany
Tosoh Bioscience – Separation & Purification Expands European Headquarters in Griesheim, Germany
BioSeparation Sustainable Biochromatography Forum ‒ Join Us in Vienna on 27 November 2024
BioSeparation Sustainable Biochromatography Forum ‒ Join Us in Vienna on 27 November 2024
Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency
Gerresheimer Gx Elite Vials: Best Drug Protection and Production Efficiency

Suppliers

Whitepapers

Saving Through Partnership and Innovation
Saving Through Partnership and Innovation
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Case Study: Exploring Machine Translation in a Global Pharmacovigilance Programme
Wound Care – Selecting the Right Antiseptic for Your Formulation
Wound Care – Selecting the Right Antiseptic for Your Formulation